BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/19/2016 8:28:00 PM | Browse: 1246 | Download: 2101
 |
Received |
|
2016-08-10 09:35 |
|
Peer-Review Started |
|
2016-08-11 10:13 |
 |
First Decision by Editorial Office Director |
|
|
|
Return for Revision |
|
2016-09-08 11:46 |
|
Revised |
|
2016-09-25 03:56 |
|
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2016-10-24 16:46 |
|
Second Decision by Editor-in-Chief |
|
2016-10-24 21:43 |
|
Final Decision by Editorial Office Director |
|
2016-10-31 15:19 |
|
Articles in Press |
|
2016-10-31 15:20 |
|
Edit the Manuscript by Language Editor |
|
2016-11-12 12:18 |
|
Typeset the Manuscript |
|
2016-12-07 16:32 |
|
Publish the Manuscript Online |
|
2016-12-19 20:29 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
|
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Medicine, Research & Experimental |
| Manuscript Type |
Observational Study |
| Article Title |
Short-term effectiveness of golimumab for ulcerative colitis: Observational multicenter study
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Marta Maia Bosca-Watts, Xavier Cortes, Marisa Iborra, Jose Maria Huguet, Laura Sempere, Gloria Garcia, Rafa Gil, MariFe Garcia, Marga Muñoz, Pedro Almela, Nuria Maroto and Jose Maria Paredes |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Marta Maia Bosca-Watts, PhD, MD, Inflammatory Bowel Disease Unit, Digestive Disease Department, University of Valencia, University Clinic Hospital of Valencia, Avda. Blasco Ibañez 17, 46010 Valencia,
Spain. inflamatoriahcuv@gmail.com
|
| Key Words |
Golimumab; Ulcerative colitis; Real-life results |
| Core Tip |
Golimumab is a fully humanized anti-tumor necrosis factor-alpha (anti-TNF) monoclonal antibody, which has recently been accepted in clinical practice. Pivotal studies have demonstrated the drug’s benefits, but real-life studies are still scarce. This observational, prospective and multi-center study in moderate-severe ulcerative colitis patients, confirmed golimumab’s short-term (14 wk) effectiveness. A high percentage of patients had responded and were off steroids at the end of follow-up. No severe adverse events were observed. Intensification (reducing the drug administration interval or increasing the dosage) may be useful in many slow-to-respond cases. |
| Publish Date |
2016-12-19 20:29 |
| Citation |
Bosca-Watts MM, Cortes X, Iborra M, Huguet JM, Sempere L, Garcia G, Gil R, Garcia M, Muñoz M, Almela P, Maroto N, Paredes JM. Short-term effectiveness of golimumab for ulcerative colitis: Observational multicenter study. World J Gastroenterol 2016; 22(47): 10432-10439 |
| URL |
http://www.wjgnet.com/1007-9327/full/v22/i47/10432.htm |
| DOI |
http://dx.doi.org/10.3748/wjg.v22.i47.10432 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
